Co-Diagnostics (DE:C970)
NASDAQ:C970
Want to see DE:C970 full AI Analyst Report?
C970 Stock Chart & Stats
€0.26
-€0.13(-13.68%)
At close: 4:00 PM EST
€0.26
-€0.13(-13.68%)
Day’s Range― - ―
52-Week Range€5.16 - €36.00
Previous CloseN/A
VolumeN/A
Average Volume (3M)0.00
Market Cap
€5.29M
Enterprise Value-€7.82M
Total Cash (Recent Filing)€11.88M
Total Debt (Recent Filing)€1.24M
Price to Earnings (P/E)―
Beta0.67
Next Earnings
May 14, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-35.25
Shares Outstanding3,602,465
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio0.03
Price to Book (P/B)0.33
Price to Sales (P/S)10.83
P/FCF Ratio-0.23
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-10.36
Revenue Forecast (FY)€471.11K
Bulls Say, Bears Say
Bulls Say
NASDAQ Relisting And ComplianceRegaining Nasdaq listing removes a material structural overhang and restores access to public capital markets, which improves ability to raise equity or debt, pursue partnerships, and execute commercialization plans. This enhances strategic optionality and credibility with customers and partners over the medium term.
CoSara India Manufacturing & South Asia ExpansionLocal manufacturing license in India and expanded distribution across South Asia create lower-cost production, faster market entry and sizable incremental addressable market. This structural capability supports TB commercialization and scale, enabling durable revenue avenues in high-burden regions.
Clinical Progress, IP Strength And AI PlatformRobust clinical enrollment, strengthening international patents and expanding assay-design AI provide sustainable competitive advantages: higher regulatory readiness, barrier to entry via IP, and long-term efficiency/product development gains. Together they materially raise commercialization odds over time.
Bears Say
Sharp Revenue Decline And Weak Commercial TractionAn ~85% revenue drop drastically erodes the company’s commercial foundation and gross-profit base. Sustained low product sales weaken the ability to cover operational overheads, delay scale-up economics, and make multi-year profitable operations contingent on successful launches and market adoption.
Persistent Cash Burn And Tight LiquidityMaterial cash depletion and multi-year negative operating cash flow constrain execution. With limited runway management must pursue financing or strategic deals, raising dilution and execution risk. Liquidity pressure hampers investment in manufacturing, regulatory filings, and commercial rollouts over coming quarters.
Pre-commercial Platform And Regulatory Execution RiskMuch of the platform still requires regulatory approvals and market access, meaning revenue depends on successful submissions, trials and partner execution. Deferrals (e.g., COVID target) and reliance on JVs add timeline and execution uncertainty, making commercialization outcomes binary and multi-step.
Co-Diagnostics News
C970 FAQ
What was Co-Diagnostics’s price range in the past 12 months?
Co-Diagnostics lowest stock price was €5.16 and its highest was €36.00 in the past 12 months.
What is Co-Diagnostics’s market cap?
Co-Diagnostics’s market cap is €5.29M.
When is Co-Diagnostics’s upcoming earnings report date?
Co-Diagnostics’s upcoming earnings report date is May 14, 2026 which is today.
How were Co-Diagnostics’s earnings last quarter?
Co-Diagnostics released its earnings results on Mar 31, 2026. The company reported -€13.927 earnings per share for the quarter, missing the consensus estimate of -€3.067 by -€10.861.
Is Co-Diagnostics overvalued?
According to Wall Street analysts Co-Diagnostics’s price is currently Overvalued.
Does Co-Diagnostics pay dividends?
Co-Diagnostics does not currently pay dividends.
What is Co-Diagnostics’s EPS estimate?
Co-Diagnostics’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Co-Diagnostics have?
Co-Diagnostics has 3,602,465 shares outstanding.
What happened to Co-Diagnostics’s price movement after its last earnings report?
Co-Diagnostics reported an EPS of -€13.927 in its last earnings report, missing expectations of -€3.067. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Co-Diagnostics?
Currently, no hedge funds are holding shares in DE:C970
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Co-Diagnostics
Co-Diagnostics, Inc. operates as a molecular diagnostics company that develops, manufactures, and sells reagents used for diagnostic tests that function through the detection and/or analysis of nucleic acid molecules in the United States and internationally. The company offers Co-Dx PCR platform, a polymerase chain reaction testing to patients in point-of-care and at-home setting. It also provides PCR diagnostic tests for COVID-19, influenza, tuberculosis, hepatitis B and C, human papillomavirus, malaria, chikungunya, dengue, and the zika virus. In addition, the company offers three multiplexed tests to test mosquitos for the identification of diseases carried by the mosquitos; molecular tools for detection of infectious diseases, liquid biopsy for cancer screening, and agricultural applications; tests that identify genetic traits in plant and animal genomes; and portable diagnostic device designed to bring PCR to patients in point-of-care and at-home settings. The company was incorporated in 2013 and is based in Salt Lake City, Utah.
C970 Earnings Call
Q4 2026
0:00 / 0:00
Earnings Call Sentiment|Neutral
The call conveyed clear strategic and operational progress — NASDAQ relisting, CoSara manufacturing license and regional expansion, CoMira JV advancement, strengthened IP, progress in clinical programs (1,200+ enrollments) and AI development — but these positives are offset by significant financial headwinds: an ~84.6% revenue decline driven by lower grant income, a large $18.9M noncash impairment that increased operating expenses, a widened GAAP net loss ($46.9M) and a ~60% reduction in cash to $11.9M. Management highlighted cost discipline and improved adjusted EBITDA excluding impairment, and articulated near-term commercialization paths (notably TB in India expected by Q3 2026), yet the company faces continued cash burn and will need to secure additional financing or strategic transactions to execute growth plans. Overall, the call signals meaningful operational milestones but material financial and execution risks remain.View all DE:C970 earnings summariesSintx Technologies
―
Vivos Therapeutics
―
Adagio Medical Holdings
―
Allurion Technologies
―
Heart Test Laboratories, Inc.
―
Options Prices
Currently, No data available
---